Our Philadelphia Anbesol drug injury lawyers offer representation to adults, children, and infants injured by using the oral pain medication Anbesol. Anbesol is an over-the counter (OTC) / non-prescription drug manufactured by Pfizer, Inc., to numb mouth, gum, and throat pain, including soreness from:
- infant teething
- sore throat
- blisters / canker sores
Anbesol and other benzocaine-containing products have been shown to cause methemoglobinemia, a condition that results in dangerously low levels of oxygen in the blood. Symptoms, signs, and consequences of methemoglobinemia may include:
- shortness of breath
- tachycardia (rapid heartrate)
- blue or gray tinted and pale skin
The U.S. Food & Drug Administration (FDA) has stated that these symptoms can appear within minutes or hours of the first use of a benzocaine oral product such as Anbesol.
For additional information on the link between oral benzocaine products and methemoglobinemia, see Philadelphia Benzocaine Drug Injury Lawyers.
Anbesol and other Benzocaine Products that May Cause Methemoglobinemia
Benzocaine is the ingredient in Anbesol and other oral pain medications that can lead to methemoglobinemia. Anbesol products that may cause methemoglobinemia include:
- Anbesol Baby
- Anbesol Jr.
- Anbesol Cold Sore Therapy
- Anbesol Maximum Strength Gel
- Anbesol Maximum Strength Liquid
Additional benzocaine oral / mouth pain numbing gels, liquids, pastes, sprays, and other substances that may result in methemoglobinemia include:
- Orajel products (see Philadephia Orajel / Baby Orajel Drug Injury Lawyers)
- Orabase (see Philadelphia Orabase Drug Injury Lawyers)
- HurriCaine products
Anbesol FDA Warnings
The FDA issued a warning in 2006 and another in 2011 about the increased risk of methemoglobinemia from use of Anbesol and other benzocaine oral pain drugs. On May 23, 2018, the FDA issued a sterner warning entitled “Risk of serious and potentially fatal blood disorder prompts FDA action on oral over-the-counter benzocaine products used for teething and mouth pain and prescription local anesthetics.” The May 2018 update advised parents to never use Anbesol or other benzocaine oral teething and mouth pain products:
- on children under age two, or
- on adults and children over age two unless the products contain specific label warnings and instructions about the risk and dangers of benzocaine-induced methemoglobinemia
The FDA also warned manufacturers of Anbesol and other benzocaine oral products that it will remove the products from the market unless manufacturers stop advertising them for use by children under the age of two.
Lawsuits brought by Philadelphia Anbesol drug injury lawyers may allege that Anbesol manufacturer, Pfizer, Inc.:
- produced and marketed a defective and unreasonably dangerous product
- engaged in misleading advertising about the effectiveness and safety of Anbesol products
- inadequately warned consumers and the public about the risk of methemoglobinemia associated with Anbesol products
- caused serious injury or death to Anbesol users
Contact our Philadelphia Anbesol Drug Injury Lawyers
Anbesol products for adults, infants, and children can result in serious illness or death from methemoglobinemia. If you or a loved one has suffered injury or death from methemoglobinemia after using an Anbesol oral pain product, you may be entitled to compensation from the manufacturer. Contact our Philadelphia Anbesol drug injury lawyers, today, for a free evaluation of your case.